Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B-cell lymphoma

Chimeric antigen receptor (CAR) T cells targeting CD19 have achieved breakthroughs in the treatment of hematological malignancies, such as relapsed/refractory non-Hodgkin lymphoma (r/rNHL); however, high rates of treatment failure and recurrence after CAR T-cell therapy are considerable obstacles to...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Tong, Chuan, Zhang, Yajing, Liu, Yang, Ji, Xingyu, Zhang, Wenying, Guo, Yelei, Han, Xiao, Ti, Dongdong, Dai, Hanren, Wang, Chunmeng, Yang, Qingming, Liu, Wanli, Wang, Yao, Wu, Zhiqiang, Han, Weidong
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2020
Assuntos:
Clinical Trials and Observations
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596761/
https://ncbi.nlm.nih.gov/pubmed/32556247
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005278
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados